Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-F63BC4D0-6225-4D78-9830-F891DEA4772E_4_en-US
DOI: https://doi.org/10.31003/USPNF_M10965_04_01
DOI Ref: ypk9e

Fentanyl Citrate Compounded Injection

DEFINITION

Fentanyl Citrate Compounded Injection contains NLT 90.0% and NMT 110.0% of the labeled amount of fentanyl ($C_{22}H_{28}N_2O$). It contains no bacteriostat or other preservative.

Prepare Fentanyl Citrate Compounded Injection, 50 mcg/mL, as follows (see *Pharmaceutical Compounding—Sterile Preparations ⟨797⟩*).

Fentanyl (as fentanyl citrate)	5000 mcg (7870 mcg)
Sodium hydroxide solution or Hydrochloric acid solution	To adjust pH
Sodium Chloride for Injection (0.9%), a sufficient quantity to make	100 mL

Dissolve *Fentanyl Citrate* in sufficient *Sodium Chloride for Injection (0.9%)* to bring to final volume. Adjust with *Sodium hydroxide solution* or *Hydrochloric acid solution* to a pH of 4–7.5. Pass the solution through a suitable sterile filter of 0.22-µm pore size into appropriate sterile syringes or container(s). [Note—Do not use a cellulose ester filter membrane for sterilization due to potential for adsorption.]

ASSAY

• **Procedure**

Solution A: Add 2.72 g of dibasic potassium phosphate to 800 mL of water. Adjust with phosphoric acid to a pH of 5.8. Add 200 mL of methanol and mix well.

Mobile phase: See *Table 1*.

Table 1

Time (min)	Methanol (%)	Solution A (%)
0.0	20	80
3.0	20	80
28.0	50	50
28.5	55	45
34.0	55	45
34.5	20	80
40	20	80

Standard solution: 2 mcg/mL of fentanyl prepared from USP Fentanyl Citrate RS in water

Sample solution: Transfer 1 mL of Injection into a 25-mL volumetric flask, and dilute with water to volume.

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm × 10-cm; 2.6-µm packing L1

Column temperature: 40°

Flow rate: 0.8 mL/min

Injection volume: 20 µL

System suitability

Sample: *Standard solution*

[NOTE—The retention time for fentanyl is about 24.6 min.]

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of fentanyl ($C_{22}H_{28}N_2O$) in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of fentanyl from the *Sample solution*

r_S = peak response of fentanyl from the *Standard solution*

C_S = concentration of fentanyl in the *Standard solution* (mcg/mL)

C_U = nominal concentration of fentanyl in the *Sample solution* (mcg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

- **pH** ⟨791⟩**:** 4.0–7.5
- **STERILITY TESTS** ⟨71⟩, *Test for Sterility of the Product to Be Examined, Membrane Filtration***:** Meets the requirements
- **BACTERIAL ENDOTOXINS TEST** ⟨85⟩**:** NMT 50.0 USP Endotoxin Units/mg of fentanyl
- **PARTICULATE MATTER IN INJECTIONS** ⟨788⟩**:** Meets the requirements

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in a light-resistant single-dose container. Store at controlled room temperature or in a refrigerator.

Change to read:

- **BEYOND-USE DATE:** ▲In the absence of passing a sterility and endotoxin test, the beyond-use dates in *Pharmaceutical Compounding—Sterile Preparations* ⟨797⟩ apply. After successful completion of sterility and endotoxin testing, NMT 90 days after the date on which it was compounded when stored at controlled room temperature or in a refrigerator.▲ (CN 1-May-2020)
- **LABELING:** Label it to indicate that it is for use in a single patient only, and to state the *Beyond-Use Date*.
- **USP REFERENCE STANDARDS** ⟨11⟩

USP Fentanyl Citrate RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
FENTANYL CITRATE COMPOUNDED INJECTION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. 50(1)

Current DocID: GUID-F63BC4D0-6225-4D78-9830-F891DEA4772E_4_en-US

DOI: https://doi.org/10.31003/USPNF_M10965_04_01

DOI ref: ypk9e